Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat + Pembrolizumab in Esophageal/GEJ Cancer
NCT03592407Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- Jul 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epacadostat in Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by City of Hope. Planned start Jul 2018; status: withdrawn.
02
Drugs
epacadostat
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03592407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03592407.